STAT June 7, 2024
Jayasree K. Iyer

Weight loss treatments have the potential to revolutionize health care in rich countries. They are driving a race among drugmakers for a slice of a market that could exceed $100 billion by 2030. But little thought has apparently been given to helping people in low- and middle-income countries, where obesity rates are soaring despite poor nutrition.

Without decisive action to develop fair access plans to these drugs for people living in poorer countries, there is a real danger that a significant medical advance will end up increasing inequality in health care. This is especially true if the rush to fund obesity research and development diverts research and development resources from other important unmet medical needs.

There is little doubt that...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Equity/SDOH, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider
Fast-Tracking Development: How Life Sciences Will Drive Speed in 2025
How Technology is Impacting Launch Strategy Timelines
mRNA Vaccine Shows Promise In Pancreatic Cancer Trial
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval

Share This Article